GET DAILY SIGNALSWhy Is Abbott Laboratories (ABT) Stock Down -3.26% Today?
Key Takeaways
- Abbott Laboratories (ABT) shares fell 3.26%, or $3.34, to $99.11 in Wednesday's session after closing at $102.45 the prior day.
- The primary catalyst was a cut to full-year 2026 comparable sales growth guidance, lowered to approximately 6% from a prior range of 6.5%–7.5%.
- A second driver was Abbott's announcement that it will spin off its Nutrition business into a separate, publicly traded company by the end of 2027.
- Third-quarter results were largely in line, but softer medical device trends — particularly continuous glucose monitor deceleration — weighed on sentiment.
- Investors are now watching how the planned separation reshapes Abbott's growth profile and whether device momentum stabilizes in the fourth quarter.
Opening Summary
Shares of ABT, the diversified healthcare giant behind brands such as FreeStyle Libre, Ensure, Similac, and a broad portfolio of medical devices and diagnostics, moved sharply lower on Wednesday, October 21, 2026. The stock declined 3.26%, or $3.34, to close near $99.11, down from the previous session's close of $102.45. The selloff was driven by a combination of a reduced full-year sales growth forecast and the company's announcement that it plans to separate its Nutrition segment into an independent public company. While third-quarter revenue edged past expectations, the guidance revision and questions about medical device momentum overshadowed the results.
Guidance Cut Overshadows Solid Third-Quarter Results
The most immediate pressure on ABT came from its revised outlook. Abbott reported third-quarter revenue of $13.01 billion, up 14.5% on a reported basis and 7% on a comparable basis, slightly ahead of consensus expectations. Adjusted earnings per share came in at $1.42, roughly in line with Wall Street forecasts. However, management lowered its full-year 2026 comparable sales growth projection to approximately 6%, down from the prior range of 6.5% to 7.5%, while narrowing its adjusted EPS guidance to a range of $5.50 to $5.55. The reduced top-line outlook signaled that growth is moderating, prompting investors to reassess near-term momentum even as the bottom line remained on track.
Nutrition Spinoff Announcement Reshapes the Story
A second, more structural catalyst was Abbott's disclosure that it intends to separate its global Nutrition business into an independent, publicly traded company by the end of 2027. The unit — which generates roughly $8.5 billion in annual sales and houses brands including Ensure, PediaSure, Glucerna, and Similac — would be led by Daniel Salvadori, currently executive vice president and group president of Established Pharmaceuticals and Nutritional Products. Abbott plans to complete the separation through a tax-free distribution of shares to existing shareholders. While management framed the move as a way to sharpen focus on its higher-growth medical devices, diagnostics, and established pharmaceuticals portfolio, the announcement added uncertainty to the investment case, contributing to the day's decline.
Medical Device Concerns Add to the Downturn
Beneath the headline results, softer trends in key growth segments weighed on sentiment. Medical device sales rose 6.9% on a reported basis to $5.83 billion, with double-digit growth in electrophysiology and rhythm management. However, analysts flagged a sequential deceleration in continuous glucose monitor sales and lighter-than-expected results in electrophysiology and diabetes, both of which are viewed as critical long-term growth drivers. The durability of that growth is a key question for investors, particularly ahead of anticipated regulatory decisions on diabetes care coverage. This segment-level caution compounded the bearish reaction to the guidance cut and the spinoff announcement.
Market Context and Trading Activity
The decline in ABT was accompanied by elevated trading volume, reflecting a broad repositioning by investors reacting to the earnings release and corporate restructuring news. The move was largely company-specific, driven by Abbott's own guidance and strategic announcements rather than a broad rotation across the healthcare sector. The stock traded below recent support levels, and the session's action suggested that short-term technical momentum had turned negative as investors digested the mixed quarter and the longer-term implications of separating the Nutrition unit.
What Comes Next for ABT
Looking ahead, investors will focus on several factors. Abbott reaffirmed the midpoint of its adjusted EPS guidance, and management expects fourth-quarter adjusted EPS of $1.62 to $1.67. The market will be watching whether medical device growth, particularly in continuous glucose monitors and electrophysiology, stabilizes in the coming quarters. Details on the Nutrition separation — including the amount of debt the new company will raise and the distribution mechanics — will also be closely scrutinized. Broader healthcare policy decisions and the planned 2027 guidance update in January represent additional catalysts. Risks include further deceleration in high-growth device categories, integration and execution challenges tied to the spinoff, and the one-time costs associated with the separation.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that have demonstrated the strongest performance under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Traders can explore this section to identify automated strategies that align with their own approach. Discover which AI robots are leading the market today by visiting the Trending AI Robots page.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABT in +2.49% Uptrend, growing for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABT advanced for three days, in 172 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ABT's RSI Oscillator exited the oversold zone, 16 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 43%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on ABT as a result. In 46 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for ABT just turned positive on October 09, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in 25 of 54 cases over the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for ABT crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 42%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ABT broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ABT entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.469) is normal, around the industry mean (2.979). P/E Ratio (33.048) is within average values for comparable stocks, (2.590). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.052). Dividend Yield (0.025) settles around the average of (0.009) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care products
Industry MedicalNursingServices
Advertisement